Community Health System is bolstering the use of multiple Masimo technologies across all of its healthcare facilities

Health Care

Masimo (NASDAQ: MASI) and Community Health System (CHS) , based in Fresno, Calif., today announced that CHS is adopting a variety of Masimo monitoring technologies and solutions at its facilities. A network of four hospitals, CHS provides all levels of care in California's Central Valley region, standardizes the use of Masimo SET ® pulse oximetry, and deploys 800 Root ® vital signs monitoring and connectivity hubs and 200 Rad-97 ® Pulse CO-Oximeters ® with NomoLine ® capnography , system-wide. In the next phase of its medical technology expansion, CHS will focus on its patient monitoring initiative, with plans to deploy Masimo Patient SafetyNet tm for centralized remote patient monitoring, leveraging Masimo Hospital Automationtm to transfer patient data in electronic medical records (EMR) to streamline the flow of nursing care and optimize patient safety. Another area of focus is expanding its intraoperative monitoring capabilities, with the planned installation of Masimo rainbow ® advanced parameters , such as noninvasive and continuous hemoglobin SpHb ® monitoring.and PVi ® Pleth Variability Index , as well as SedLine ® brain function monitoring , O3 ® regional oximetry and LiDCO ® hemodynamic monitoring . Joe Kiani , Founder and CEO, Masimo: “We are honored to work with a partner like CHS to improve patient outcomes across the continuum of care. Its dedication to ensuring that its clinicians have access to the tools they need to provide patients with the highest quality care possible? the most advanced non-invasive monitoring technologies, the most versatile patient monitors, the most sophisticated automation and connectivity solutions? is a source of inspiration. » Daniel Davis, RN, Chief Nursing Officer and Senior Vice President, CHS: “This expanded partnership allows us to integrate Masimo's best-in-class noninvasive monitoring technology into every hospital in our healthcare system. We expect it to optimize workflows and provide additional insight into patient conditions to help us improve outcomes. » Cheri Provancha, DBA, DML, Vice President, Supply Chain, Safety and Clinical Engineering, CHS: "We are excited to deepen our relationship with Masimo and provide our talented clinicians with advanced noninvasive technologies, monitoring and automation solutions they can rely on to provide the best care possible to Central Valley patients. » CHS is a private, not-for-profit healthcare network based in Fresno, California. The system operates four hospitals and a cancer institute as well as several long-term care, outpatient and other health care facilities. In 2014, CHS rolled out Masimo SET ® for Women and Children's Services and Neonatal Intensive Care at the Community Regional Medical Center campus, and has since standardized its use across all areas of care across its campuses. CHS' positive experience with Masimo technology? for both clinicians and patients? was the driving force behind this multi-pronged expansion and standardized use of Masimo technologies. @Masimo | #Masimo About Masimo Masimo (NASDAQ: MASI) is a global medical technology company that develops and produces a wide range of industry-leading monitoring technologies, including innovative measurements, sensors, patient monitors, and automation and connectivity. Additionally, Masimo Consumer Audio operates eight legendary audio brands, including Bowers & Wilkins, Denon, Marantz and Polk Audio. Our mission is to improve lives, improve patient outcomes and reduce the cost of care. Masimo SET ® Measure-through Motion and Low Perfusiontm Pulse Oximetry , introduced in 1995, has been shown in more than 100 independent, objective studies to outperform other pulse oximetry technologies.® has also been shown to help clinicians reduce severe retinopathy of prematurity in neonates, 2 improve screening for cardiovascular disease in neonates 3 and, when used for continuous monitoring with Masimo Patient SafetyNettm in post-surgical wards, reduce rapid response team activations, ICU transfers and costs. 4-7 The use of the Masimo SET ® system is estimated at more than 200 million patients in major hospitals and other healthcare facilities worldwide, 8and is the primary pulse oximetry in 9 of the top 10 ranked hospitals in the 2022-2023 U.S. News and World Report Best Hospitals Honor Roll. 9 In 2005, Masimo introduced rainbow ® Pulse CO-Oximetry technology, enabling noninvasive and continuous monitoring of blood components that previously could only be measured invasively, including total hemoglobin (SpHb ® ) , blood oxygen (SpOCtm), carboxyhemoglobin (SpCO ® ), methemoglobin (SpMet ® ), pleth variability index (PVi ® ), RPVitm (rainbow ®PVi), and oxygen reserve index (ORitm). In 2013, Masimo launched the Root ® patient monitoring and connectivity platform, designed to be as flexible and expandable as possible to make it easy to add other Masimo and third-party monitoring technologies; key Masimo additions include next-generation SedLine ® brain function monitoring , O3 ® regional oximetry and ISAtm capnography with NomoLine ® sample lines . The Masimo Family of Pulse CO- Oximeters®for continuous monitoring and spot-checking includes devices designed for use in a variety of clinical and non-clinical scenarios, including wireless handheld technology, such as Radius-7 ® , Radius PPG ® and Radius VSMtm, wearable devices such as Rad-67 ® , fingertip pulse oximeters like MightySat ® Rx, and devices available both in the hospital and at home, such as Rad-97 ® . Masimo Hospital and Home automation and connectivity solutions are centered on the Masimo Hospital Automationtm platform, and include Iris ® Gateway, iSironatm, Patient SafetyNet, Replica ® , Halo ION® , UniView ® , UniView:60tm and Masimo SafetyNet ® . Its growing portfolio of health and wellness solutions includes Radius Tº ® and the Masimo W1tm watch. Additional information about Masimo and its products is available at www.masimo.com . Published clinical studies on Masimo products can be viewed at www.masimo.com/evidence/featured-studies/feature/ . ORi and RPVi have not received FDA 510(k) clearance and are not available for sale in the United States. Use of the Patient SafetyNet trademark is under license from University HealthSystem Consortium. References Published clinical studies on pulse oximetry and the benefits of Masimo SET ® are available on our website at http://www.masimo.com . Comparative studies include independent, objective studies that consist of abstracts presented at scientific meetings and peer-reviewed journal articles. Castillo A et al. Prevention of Retinopathy of Prematurity in Preterm Infants through Changes in Clinical Practice and SpO 2 Technology. Acta Paediatr. 2011 Feb;100(2):188-92. de-Wahl Granelli A et al. Impact of pulse oximetry screening on the detection of duct dependent congenital heart disease: a Swedish prospective screening study in 39,821 newborns. BMJ. 2009;Jan 8;338. Taenzer A et al. Impact of pulse oximetry surveillance on rescue events and intensive care unit transfers: a before-and-after competition study. Anaesthesiology . 2010:112(2):282-287. Taenzer A et al. Postoperative Monitoring? The Dartmouth Experience. Anesthesia Patient Safety Foundation Newsletter . Spring-summer 2012. McGrath S et al. Surveillance Monitoring Management for General Care Units: Strategy, Design, and Implementation. The Joint Commission Journal on Quality and Patient Safety . 2016 Jul;42(7):293-302. McGrath S et al. Inpatient Respiratory Arrest Associated With Sedative and Analgesic Medications: Impact of Continuous Monitoring on Patient Mortality and Severe Morbidity. J Patient Saf. 2020 14 Mar. DOI: 10.1097/PTS.0000000000000696. Estimate: Data on file with Masimo. http://health.usnews.com/health-care/best-hospitals/articles/best-hospitals-honor-roll-and-overview . Forward-looking statements This press release contains forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, among others, statements regarding the potential effectiveness of Masimo's surveillance technologies, monitoring devices, and automation and connectivity solutions, and statements regarding CHS' enhanced use of various Masimo technologies. These forward-looking statements are based on current expectations about future events that affect us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control. and could cause actual results to differ materially and adversely from those contained in our forward-looking statements due to various risk factors, including: risks related to our assumptions regarding the repeatability of clinical results; risks related to our belief that Masimo's unique noninvasive measurement technologies, including Masimo's monitoring technologies, monitoring devices, and automation and connectivity solutions, contribute to positive clinical outcomes and safety patients ; risks related to our belief that Masimo's noninvasive medical advances offer cost-effective solutions and unique benefits; the risks that CHS will fail to realize the expected benefits of the Masimo technologies or fail to deploy the Masimo technologies in accordance with the plans described in this release; risks relating to COVID-19; and other factors described in the "Risk Factors" section of our most recent reports filed with the Securities and Exchange Commission ("SEC"), which are available free of charge on the SEC's website atwww.sec.gov . Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove to be correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of today's date. We do not undertake to update, modify or clarify these statements or the “Risk Factors” contained in our latest reports filed with the SEC, whether as a result of new information, future events or otherwise, except if required by applicable securities laws. The text of the press release resulting from a translation should in no way be considered official. The only authentic version of the press release is that of the press release in its original language. The translation will always have to be compared with the source text, which will set a precedent.

contend article

Community Health System is bolstering the use of multiple Masimo technologies across all of its healthcare facilities